NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02807636,Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma,https://clinicaltrials.gov/study/NCT02807636,IMvigor130,COMPLETED,"A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer.",YES,Urothelial Carcinoma,DRUG: Atezolizumab|DRUG: Carboplatin|DRUG: Gemcitabine|OTHER: Placebo|DRUG: Cisplatin,"Investigator Assessed Progression-Free Survival (PFS) in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm, PFS is defined as the time from randomization to the first documented disease progression as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever occurs first., Baseline up to first documented disease progression or death, whichever occurs first (up to approximately 35 months)|Overall Survival (OS) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm, OS is defined as the time from randomization to death due to any cause., Baseline until death due to any cause (up to approximately 73 months)|Overall Survival (OS) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm, OS is defined as the time from randomization to death due to any cause., Baseline until death due to any cause (up to approximately 73 months)","Objective Response Rate (ORR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm, Objective response rate (ORR) is defined as the proportion of participants with a confirmed objective response, either complete response (CR) or partial response (PR), observed on two assessments \>= 28 days apart per RECIST v1.1, based on investigator assessment. The analysis population for ORR will be all randomized participants with measurable disease at baseline., Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)|Objective Response Rate (ORR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm, Objective response rate (ORR) is defined as the proportion of participants with a confirmed objective response, either complete response (CR) or partial response (PR), observed on two assessments \>= 28 days apart per RECIST v1.1, based on investigator assessment. The analysis population for ORR will be all randomized participants with measurable disease at baseline., Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)|Duration of Response (DOR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm, Duration of response (DOR) is defined for participants with an objective response as the time from the first documented objective response to documented disease progression per RECIST v1.1, based on investigator assessment, or death due to any cause, whichever occurs first., From first documented objective response (CR or PR) to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)|Duration of Response (DOR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm, Duration of response (DOR) is defined for participants with an objective response as the time from the first documented objective response to documented disease progression per RECIST v1.1, based on investigator assessment, or death due to any cause, whichever occurs first., From first documented objective response (CR or PR) to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)|IRF-PFS, Independent review facility PFS (IRF-PFS) is defined as the time from randomization to the first documented disease progression as determined by blinded independent central review with use of RECIST v1.1, or death due to any cause, whichever occurs first., Randomization to first documented disease progression or death from any cause (up to 35 months)|OS Event Free Rate Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm, Overall Survival (OS) Event Free Rate at 1 Year., Year 1|OS Event Free Rate in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm, Overall Survival (OS) Event Free Rate at 1 Year., Year 1|PFS Event Free Rate, Progression Free Survival (PFS) Event Free Rate at Year 1, Year 1|Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm, Time to deterioration in global health status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm., Up to approximately 73 months|Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm, Time to deterioration in global health status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 in the Placebo+Chemo Arm versus Atezolizumab Monotherapy Arm., Up to approximately 73 months|Time to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm, Median time to deterioration in physical function as measured by the QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm., Up to approximately 73 months|Time to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm, Median time to deterioration in physical function as measured by the QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab Monotherapy Arm., Up to approximately 73 months|Maximum Atezolizumab Serum Concentration, Maximum atezolizumab serum concentration., Cycle 1 Day 1|Minimum Atezolizumab Serum Concentration, Minimum atezolizumab serum concentration., Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 8 Day 1, Cycle 16 Day 1, Cycle 24 Day 1, Cycle 32 Day 1, Day 120 post dose of last blinded atezolizumab treatment, and study drug early discontinuation|Percentage of Participants With Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs), Percentage of participants with Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs)., Up to approximately 35 months|Investigator-Assessed Progression-Free Survival (INV-PFS) in Participants Treated With Atezolizumab Monotherapy Arm Compared With Placebo+Gemcitabine+Carboplatin/Cisplatin Arm, PFS is defined as the time from randomization to the first documented disease progression as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever occurs first., Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (assessed at baseline, every 9 weeks for 54 weeks and every 12 weeks thereafter up to 35 months)|Percentage of Participants With Grade 3-4 Adverse Events (AEs), Percentage of participants with Grade 3-4 Adverse Events (AEs) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0., Baseline up to 93 months|Percentage of Participants With Grade 5 Adverse Events (AEs), Percentage of participants with Grade 5 Adverse Events (AEs) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0., Baseline up to 93 months|Percentage of Participants With Serious Adverse Events (SAEs), Percentage of participants with Serious Adverse Events (SAEs) assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0., Baseline up to 93 months|Percentage of Participants With Adverse Events (AEs) Leading to Withdrawal of Any Study Treatment, Percentage of participants with Adverse Events (AEs) leading to withdrawal of any study treatment assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0., Baseline up to 93 months|Percentage of Participants With Atezolizumab-Specific Adverse Events of Special Interest (AESIs), Percentage of participants with atezolizumab-specific Adverse Events of Special Interest (AESIs) Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0., Baseline up to 93 months",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,1213,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",WO30070|2016-000250-35,2016-06-30,2022-08-31,2024-02-12,2016-06-21,2023-12-13,2025-03-25,"Highlands Oncology Group, Rogers, Arkansas, 72758, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, 93401, United States|Yale School of Medicine, New Haven, Connecticut, 06520-8032, United States|Norwalk Hospital, Norwalk, Connecticut, 06856, United States|Christina Care Institutional Review Board, Newark, Delaware, 19713, United States|Florida Cancer Specialists, Fort Myers, Florida, 33916, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, 32824, United States|Florida Cancer Specialists (St. Petersburg ? St. Anthony?s Professional Building), Saint Petersburg, Florida, 33705, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Parkview Research Center, Fort Wayne, Indiana, 46845, United States|Norton Cancer Institute, Louisville, Kentucky, 40402, United States|East Jefferson Hematology Oncology, Metairie, Louisiana, 70006, United States|Park Nicollet Clin-Cancer Ctr, Saint Louis Park, Minnesota, 55426, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89148, United States|Mount Sinai School of Medicine - Tisch Cancer Institute, New York, New York, 10029, United States|University of North Carolina, Lineberger Cancer Ctr, Chapel Hill, North Carolina, 27599, United States|Bon Secours - St. Francis Hospital, Greenville, South Carolina, 29607, United States|Sarah Cannon Research Institute / Tennessee Oncology, Nashville, Tennessee, 37203, United States|Macquarie University Hospital, Macquarie University, New South Wales, 2109, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, 4029, Australia|Lyell McEwin Hospital, Adelaide, South Australia, 5112, Australia|Box Hill Hospital, Box Hill, Victoria, 3128, Australia|Cabrini Medical Centre, Malvern, Victoria, 3144, Australia|Sunshine Hospital, St Albans, Victoria, DUMMY_VALUE, Australia|GHdC Site Notre Dame, Charleroi, B6000, Belgium|AZ Sint Lucas (Sint Lucas), Gent, 9000, Belgium|UZ Leuven Gasthuisberg, Leuven, 3000, Belgium|CHC MontLégia, Liege, 4000, Belgium|Clinical center University of Sarajevo, Sarajevo, 71000, Bosnia and Herzegovina|CETUS Hospital Dia Oncologia, Belo Horizonte, Minas Gerais, 30110022, Brazil|Hospital Luxemburgo, Belo Horizonte, Minas Gerais, 31190-131, Brazil|Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda, Ijui, Rio Grande Do Sul, 98700-000, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, Rio Grande Do Sul, 90035-903, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Rio Grande Do Sul, 91350-200, Brazil|Clinica Viver, Santa Maria, Rio Grande Do Sul, 97015-450, Brazil|Clinica de Neoplasias Litoral, Itajai, Santa Catarina, 88301-220, Brazil|Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, São Paulo, 15090-000, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, São Paulo, 01246-000, Brazil|Beneficencia Portuguesa de Sao Paulo, Sao Paulo, São Paulo, 01323-900, Brazil|Clinicas Oncologicas Integradas - COI, Rio de Janeiro, 22793-080, Brazil|Arthur J.E. Child Comprehensive Cancer Center-Calgary, Calgary, Alberta, T2N 4N2, Canada|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|BC Cancer Agency, CSI, Kelowna, British Columbia, V1Y 5L3, Canada|Dr. Georges L. Dumont University Hospital Centre, Moncton, New Brunswick, E1C8X3, Canada|Juravinski Cancer Clinic, Hamilton, Ontario, L8V 5C2, Canada|Lakeridge Health Center, Oshawa, Ontario, L1G 2B9, Canada|North York General Hospital, Toronto, Ontario, M2K 1E1, Canada|Bradford Hill Centro de Investigaciones Clinicas, Recoleta, 8420383, Chile|OrlandiOncología, Santiago, 7500713, Chile|Fundacion Arturo Lopez Perez, Santiago, Providencia, Chile|Clinica Alemana, Vitacura, 0, Chile|Beijing Friendship Hospital, Beijing, 100050, China|Peking Union Medical College Hospital, Beijing, 100730, China|Chongqing Cancer Hospital, Chongqing, 400030, China|Sun Yat-sen Memorial Hospital, Guangzhou, 510000, China|Jiangsu Cancer Hospital, Nanjing, 210009, China|Fudan University Shanghai Cancer Center, Shanghai, 200032, China|Zhongshan Hospital Fudan University, Shanghai, 200032, China|Huadong Hospital Affiliated to Fudan University, Shanghai, 200040, China|The 2nd Hospital of Tianjin Medical University, Tianjin, 201203, China|Masarykuv onkologicky ustav, Brno, 656 53, Czechia|Fakultni nemocnice Olomouc, Olomouc, 779 00, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 128 08, Czechia|University Hospital Motol, Praha 5, 15006, Czechia|East Tallinn Central Hospital, Tallinn, 10138, Estonia|North Estonia Medical Centre Foundation, Tallinn, 13419, Estonia|Oulu University Hospital, Oulu, 90029, Finland|Turku Uni Central Hospital, Turku, 20520, Finland|Research institute for Clinical Medicine, Tbilisi, 0112, Georgia|National Center of Urology, Tbilisi, 0144, Georgia|Alexandras General Hospital of Athens, Athens, 11528, Greece|University Hospital of Patras Medical Oncology, Patras, 265 04, Greece|Princess Margaret Hospital, Hong Kong, DUMMY_VALUE, Hong Kong|Queen Elizabeth Hospital, Hong Kong, DUMMY_VALUE, Hong Kong|Queen Mary Hospital, Hong Kong, DUMMY_VALUE, Hong Kong|The Chinese University of Hong Kong, Hong Kong, DUMMY_VALUE, Hong Kong|Rambam Health Care Campus, Haifa, 3109601, Israel|Azienda Ospedaliera A. Cardarelli, Napoli, Campania, 80131, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola, Meldola, Emilia-Romagna, 47014, Italy|A.O. Universitaria Policlinico Di Modena, Modena, Emilia-Romagna, 41100, Italy|Policlinico Umberto i di Roma, Roma, Lazio, 00161, Italy|Az. Osp. Uni Ria San Martino, Genova, Liguria, 16132, Italy|Irccs Istituto Nazionale Dei Tumori (Int), Milano, Lombardia, 20133, Italy|Istituto Clinico Humanitas, Rozzano, Lombardia, 20089, Italy|A.O CITTA' DELLA SALUTE E DELLA SCIENZA D. - Presidio San Lazzaro, Torino, Piemonte, 10126, Italy|IRCCS Ospedale Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Puglia, 71013, Italy|Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato, Arezzo, Toscana, 52100, Italy|Azienda Ospedaliera S. Maria - Terni, Terni, Umbria, 05100, Italy|IRCCS Istituto Oncologico Veneto (IOV), Padova, Veneto, 35128, Italy|Nagoya University Hospital, Aichi, 466-8560, Japan|Hirosaki University Hospital, Aomori, 036-8563, Japan|National Hospital Organization Shikoku Cancer Center, Ehime, 791-0280, Japan|Gunma University Hospital, Gunma, 371-8511, Japan|National Hospital Organization Hokkaido Cancer Center, Hokkaido, 003-0804, Japan|University of Tsukuba Hospital, Ibaraki, 305-8576, Japan|Kanazawa University Hospital, Ishikawa, 920-8641, Japan|Kumamoto University Hospital, Kumamoto, 860-8556, Japan|Niigata University Medical & Dental Hospital, Niigata, 951-8520, Japan|Osaka Metropolitan University Hospital, Osaka, 545-8586, Japan|Kindai University Hospital, Osaka, 589-8511, Japan|Toranomon Hospital, Tokyo, 105-8470, Japan|The Cancer Institute Hospital, JFCR, Tokyo, 135-8550, Japan|Keio University Hospital, Tokyo, 160-8582, Japan|Kyungpook National University Medical Center, Daegu, 41404, Korea, Republic of|Gachon University Gil Medical Center, Incheon, 21565, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Hospital Kuala Lumpur, Kuala Lumpur, FED. Territory OF Kuala Lumpur, 50586, Malaysia|University Malaya Medical Centre, Kuala Lumpur, FED. Territory OF Kuala Lumpur, 59100, Malaysia|Consultorio Médico, Zapopan, Jalisco, 45040, Mexico|Health Pharma Professional Research, CD Mexico, Mexico CITY (federal District), 03810, Mexico|IMSS Hospital General de Zona No. 48 S. Pedro Xalpa, Mexico CITY (federal District), 02710, Mexico|Cancerología, Queretaro, 76090, Mexico|Martini Ziekenhuis, Groningen, 9728 NT, Netherlands|Hagaziekenhuis, locatie Leyweg, Nl -den Haag, 2504 LN, Netherlands|Zuyderland Medisch Centrum, Sittard-Geleen, 6162 BG, Netherlands|Isala Klinieken, Sophia, Zwolle, 8025 AB, Netherlands|Bialostockie Centrum Onkologii, Bialystok, 15-027, Poland|Przychodnia Lekarska KOMED, Roman Karaszewski, Konin, 62-500, Poland|Szpital Uniwersytecki w Krakowie, Kraków, 31-501, Poland|Woj.Wielospecjalistyczne Centrum Onkologii i Traumatologii, Lodz, 93-513, Poland|Oddzial Chemioterapii Szpitala Klinicznego Nr 1 w Poznaniu, Poznan, 60-569, Poland|NU-MED Centrum Diagnostyki i Terapii Onkologicznej, Tomaszów Mazowiecki, 97-200, Poland|Szpital Grochowski im. dr med. Rafa?a Masztaka Sp. z o.o., Warszawa, 04-073, Poland|Hospital de Santa Maria, Lisboa, 1649-035, Portugal|IPO do Porto, Porto, 4200-072, Portugal|Spitalul Judetean de Urgenta Dr Constantin Opris, Baia Mare, 430031, Romania|Institute Of Oncology Bucharest, Bucharest, 022338, Romania|Oncology Center Sf. Nectarie, Craiova, 200347, Romania|SBEI of HPE ?Bashkir State Medical University? of MoH RF, UFA, Baskortostan, 450000, Russian Federation|Krasnoyarsk Regional Oncology Dispensary n.a. Krizhanovsky, Krasnoyarsk, Krasnodar, 660133, Russian Federation|Blokhin Cancer Research Center, Moscow, Moskovskaja Oblast, 115478, Russian Federation|Russian Scientific Center of Roentgenoradiology, Moscow, Moskovskaja Oblast, 117997, Russian Federation|P.A. Herzen Oncological Inst., Moscow, Moskovskaja Oblast, 125248, Russian Federation|Privolzhsk Regional Medical Center, Nizhny Novgorod, Niznij Novgorod, 603001, Russian Federation|SBEI HPE ""The First St.Petersburg State Medical University n.a. acad. I.P.Pavlova""of MoH of RF, St Petersburg, Sankt Petersburg, 197089, Russian Federation|Sverdlovsk Regional Clinical Hospital 1, Yekaterinburg, Sverdlovsk, 620102, Russian Federation|Ivanovo Regional Oncology Dispensary, Ivanovo, 153040, Russian Federation|Clinical Center of Serbia, Belgrade, 11000, Serbia|Clinical Centre Nis, Clinic for Oncology, NIs, 18000, Serbia|Oncology Institute of Vojvodina, Sremska Kamenica, 21204, Serbia|National University Hospital, Singapore, 119228, Singapore|National Cancer Centre, Singapore, 169610, Singapore|Oncocare Cancer Centre, Singapore, DUMMY_VALUE, Singapore|Institute of Oncology Ljubljana, Ljubljana, 1000, Slovenia|Cancercare, Port Elizabeth, 6045, South Africa|Wilgers Oncology Centre, Pretoria, 0001, South Africa|Sandton Oncology Medical Group, Sandton, 2196, South Africa|Hospital General Universitario de Elche, Elche, Alicante, 03203, Spain|Complejo Hospitalario de Althaia, Manresa, Barcelona, 08243, Spain|Corporacio Sanitaria Parc Tauli, Sabadell, Barcelona, 08208, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, 39008, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Islas Baleares, 07014, Spain|Clinica Universitaria de Navarra, Pamplona, Navarra, 31008, Spain|Hospital Alvaro Cunqueiro, Vigo, Pontevedra, 36312, Spain|Hospital de Basurto, Bilbao, Vizcaya, 48013, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, 02006, Spain|Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, 08035, Spain|Hospital Clinic de Barcelona. Unidad de Nuevas Terapias, Barcelona, 08036, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 08041, Spain|Institutio Catalan De Oncologia, Barcelona, 08907, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, 08916, Spain|Complejo Asistencial Universitario De Burgos, Burgos, 09006, Spain|Hospital San Pedro De Alcantara, Caceres, 10003, Spain|Hospital Provincial de Castellon, Castellon, 12002, Spain|Hospital Universitario Reina Sofia, Cordoba, 14004, Spain|Hospital Universitario Virgen de las Nieves, Granada, 18014, Spain|Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico, Jaen, 23007, Spain|Complejo Asistencial Universitario de Leon, Leon, 24071, Spain|Hospital Universitario Lucus Augusti, Lugo, 27003, Spain|Hospital General Universitario Gregorio Marañon, Madrid, 28007, Spain|Hospital Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario Clínico San Carlos, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|Hospital Universitario de Toledo, Toledo, 45007, Spain|Hospital Universitario la Fe, Valencia, 46026, Spain|Hospital Clinico Universitario Lozano Blesa, Zaragoza, 50009, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain|Chang Gung Medical Foundation - Kaohsiung, Kaohisung, DUMMY_VALUE, Taiwan|China Medical University Hospital, Taichung, 40447, Taiwan|Taichung Veterans General Hospital, Taichung, 407, Taiwan|National Cheng Kung Uni Hospital, Tainan, 704, Taiwan|National Taiwan Uni Hospital, Taipei City, 10048, Taiwan|Chang Gung Medical Foundation-Linkou, Urinary Oncology, Taoyuan, 333, Taiwan|Vajira Hospital, Bangkok, 10300, Thailand|Chulalongkorn Hospital, Bangkok, 10330, Thailand|Faculty of Med. Siriraj Hosp., Bangkok, 10700, Thailand|Maharaj Nakorn Chiang Mai Hospital, ChiangMai, 50200, Thailand|Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital, Adana, 01250, Turkey|Ankara Bilkent City Hospital, Ankara, 06800, Turkey|Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi, Edirne, 22030, Turkey|Bezmi Alem Vakif University Medical School, Istanbul, 34093, Turkey|Istanbul University Cerrahpa?a-Cerrahpa?a Medical Faculty, Istanbul, 34098, Turkey|Hacettepe Uni Medical Faculty Hospital, S?hhiye, Ankara, 06100, Turkey|19 Mayis University Medical Faculty, Samsun, 55139, Turkey|Regional Clinical Center of Urology and Nephrology n.a. V.I. Shapoval Department of Urology #4, Kharkiv, Kharkiv Governorate, 61037, Ukraine|CI Dnipropetrovsk CMCH #4 MA of MOHU Ch of Oncology and MR, Dnipropetrovsk, 49102, Ukraine|Zaporizhzhia Regional Clinic, Zaporizhzhia, 69600, Ukraine|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|University College London Hospitals NHS Foundation Trust - University College Hospital, London, NW1 2BU, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom|The York Hospital, York, YO31 8HE, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/36/NCT02807636/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/36/NCT02807636/SAP_001.pdf"
